Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at wallstreetsectors.com, will continue to monitor these energy companies to see if the momentum continues. WallStreetSectors.com is also looking into these tickers BMRN, PEPG, BLCO, COO, SAGE..
Recent NMTR Stock Price: $0.28
Summary: 9 Meters Biopharma, Inc. is a rare, orphan and unmet needs focused GI company. It's advancing NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for Short Bowel Syndrome, a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom. 9 Meters Biopharma Inc., formerly known as Innovate Bioph, is based in Raleigh, United States.
Gary Nachman analyst at BMO Capital reiterates coverage on 9 Meters Biopharma (NMTR) stock in the energy sector with a Buy rating and has set NMTR's stock price target at $ 3.
TipRanks.com reports that 9 Meters Biopharma currently has 4 analysts offering 12-month price targets on NMTR and the consensus is a Strong Buy rating with an average stock price target of $2.67. The most recent NMTR stock price we have is $0.28 and we are not making any NMTR forecasts at this time.
In addition, TradingView issued a Strong Sell rating for NMTR over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on NMTR. wallstreetsectors.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on NMTR, please click here >>
Verona Pharma, VRNA
Recent VRNA Stock Price: $4
Summary: Verona Pharma plc is a clinical-stage biopharmaceutical company. It researches, discovers and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. Verona Pharma plc is based in London, the United Kingdom.
Joon Lee analyst at Truist Financial reiterates coverage on Verona Pharma (VRNA) stock in the energy sector with a Buy rating and has set VRNA's stock price target at n/a.
TipRanks.com reports that Verona Pharma currently has 3 analysts offering 12-month price targets on VRNA and the consensus is a Strong Buy rating with an average stock price target of $21.50. The most recent VRNA stock price we have is $4 and we are not making any VRNA forecasts at this time.
In addition, TradingView issued a Sell rating for VRNA over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on VRNA. wallstreetsectors.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on VRNA, please click here >>
Recent DXCM Stock Price: $72.21
Summary: DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. A key element of DexCom's monitoring system technology is the continuous measure of patient's blood glucose level and transmission of that information to a small cell phone-sized receiver in real time. The company's monitoring systems aim to provide real-time continuous blood glucose values, trend data and alerts to assist patients in managing their blood glucose levels.
Chris Cooley analyst at Stephens reiterates coverage on Dexcom (DXCM) stock in the energy sector with a Buy rating and has set DXCM's stock price target at $ 87.
TipRanks.com reports that Dexcom currently has 11 analysts offering 12-month price targets on DXCM and the consensus is a Strong Buy rating with an average stock price target of $119.95. The most recent DXCM stock price we have is $72.21 and we are not making any DXCM forecasts at this time.
In addition, TradingView issued a Sell rating for DXCM over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on DXCM. wallstreetsectors.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on DXCM, please click here >>
The editors at wallstreetsectors.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
WallStreetSectors.com keeps investors investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to WallStreetSectors.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.